Evogene logo

EvogeneNASDAQ: EVGN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

15 October 2010

Next earnings report:

15 November 2024

Last dividends:

N/A

Next dividends:

N/A
$13.57 M
-88%vs. 3y high
20%vs. sector
-vs. 3y high
-vs. sector
-64%vs. 3y high
79%vs. sector
-98%vs. 3y high
29%vs. sector

Price

pre-market | 10 min ago
$2.53+$0.15(+6.30%)

Dividend

No data over the past 3 years
$914.00 K$2.85 M
$914.00 K-$5.42 M

Analysts recommendations

Institutional Ownership

EVGN Latest News

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
prnewswire.com29 October 2024 Sentiment: -

The shipment, comprising over 100 tons, was delivered to company's customer in Africa REHOVOT, Israel , Oct. 29, 2024 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company for oil production for bio-based products and biofuel, and a subsidiary of Evogene Ltd.

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
prnewswire.com08 October 2024 Sentiment: POSITIVE

Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel , Oct. 8, 2024 /PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd.

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
prnewswire.com23 August 2024 Sentiment: POSITIVE

REHOVOT, Israel , Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering.

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
prnewswire.com12 August 2024 Sentiment: POSITIVE

REHOVOT, Israel , Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
prnewswire.com23 July 2024 Sentiment: NEUTRAL

Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued andoutstanding REHOVOT, Israel , July 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024.

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
prnewswire.com02 July 2024 Sentiment: POSITIVE

Lavie Bio successfully completed testing of Yalos™ for winter wheat and will commence sales across the US for the 2024-2025 season REHOVOT, Israel , July 2, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.

Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
prnewswire.com25 June 2024 Sentiment: POSITIVE

Current castor seed production is expected to support the supply of the new order in 2024, valued at ~ $440K  REHOVOT, Israel , June 25, 2024 /PRNewswire/ -- Casterra Ag Ltd ., a subsidiary of Evogene Ltd.

Evogene Reports First Quarter 2024 Financial Results
prnewswire.com23 May 2024 Sentiment: POSITIVE

Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024.

Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research07 March 2024 Sentiment: NEGATIVE

Evogene (EVGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago.

Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
Zacks Investment Research12 January 2024 Sentiment: POSITIVE

Does Evogene (EVGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

What type of business is Evogene?

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

What sector is Evogene in?

Evogene is in the Healthcare sector

What industry is Evogene in?

Evogene is in the Biotechnology industry

What country is Evogene from?

Evogene is headquartered in Israel

When did Evogene go public?

Evogene initial public offering (IPO) was on 15 October 2010

What is Evogene website?

https://www.evogene.com

Is Evogene in the S&P 500?

No, Evogene is not included in the S&P 500 index

Is Evogene in the NASDAQ 100?

No, Evogene is not included in the NASDAQ 100 index

Is Evogene in the Dow Jones?

No, Evogene is not included in the Dow Jones index

When was Evogene the previous earnings report?

No data

When does Evogene earnings report?

The next expected earnings date for Evogene is 15 November 2024